Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G)

Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G) - Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043200

Enrollment

160

Registered

2021-02-01

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric or colorectal neuroendocrine carcinoma (NEC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Meets one of the following histological diagnosis requirements taking immunohistochemical staining into account. 1. Pathological examination of a resected specimen led to a diagnosis of NEC 2. Diagnosed as Mixed adenoneuroendocrine carcinoma (tumors in which there is a mixture of >=30% of adenocarcinoma and NEC) based on resected specimen 2) The primary organ is the stomach or colorectum. 3) Distant metastasis or recurrent lesions that cannot be radically resected. 4) Refractory or intolerant to systemic platinum-based chemotherapy in the primary treatment. The secondary treatment has been implemented within 6 months from the final administration of the primary treatment. 5) Ramucirumab containing chemotherapy (secondary treatment in case of no ramucirumab) was started during the following periods: 1. Gastric NEC: Between March 2015 and June 2020 2. Colorectal NEC: Between May 2016 and June 2020 6) ECOG PS is determined as follows: 1. Group A (cases that include ramucirumab containing chemotherapy for secondary treatment or beyond) ECOG PS at the start of ramucirumab combination therapy is 0-2. 2. Group B (cases that do not include ramucirumab containing chemotherapy for secondary treatment or beyond) ECOG PS at the start of the secondary treatment is 0-2.

Exclusion criteria

Exclusion criteria: 1) History of ramucirumab administration before the start of the secondary treatment 2) If the attending physician or study supervising physician determined the case to be unsuitable

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression-free survival Response rate Disease control rate Duration of response Adverse event	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results